Merus NV 주식 가격. MRUS - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

가격

40.81

매수가

38.99

매도가

42.88

거래량

390,393

40.455 일간 변동폭 42.13

35.06 52주 범위 61.61

market_cap

2.794B

전일 종가

41.57

개장가

41.82

최근 거래 시간

150

40.81

(formt)

마지막 거래 시간

재정 규모

US$ 16,068,028

VWAP

41.1586

평균 볼륨(3m)

638,255

발행 주식

68,463,681

배당수익률

주가수익률

0.00

주당순이익(EPS)

매출

43.95M

순이익

-154.94M

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. 더 보기

섹터

Gen Med & Surgical Hospitals

산업

Gen Med & Surgical Hospitals

웹사이트

www.merus.nl

본부

Utrecht, Utrecht, Nld

설립됨

Merus NV is listed in the Gen Med & Surgical Hospitals sector of the 나스닥 with ticker MRUS. The last closing price for Merus NV was US$41.57. Over the last year, Merus NV shares have traded in a share price range of US$ 35.06 to US$ 61.61.

Merus NV currently has 68,463,681 shares in issue. The market capitalisation of Merus NV is US$2.85 billion.

Form 4 - Statement of changes in beneficial ownership of securities

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+;...

Form 8-K - Current report

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

BIZENGRI® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1Merus and...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	-0.3	-0.729749452688	41.11	42.465	39.291	582620	41.03247268	CS
4	-1.65	-3.88601036269	42.46	47.75	37.77	712302	41.05934357	CS
12	-13.73	-25.1741840851	54.54	55.0099	37.77	638255	43.34890709	CS
26	-13.56	-24.9402243884	54.37	55.39	37.77	554425	47.16347019	CS
52	5.14	14.4098682366	35.67	61.61	35.06	683745	48.89845804	CS
156	16.97	71.182885906	23.84	61.61	12.03	444827	35.82430038	CS
260	24.05	143.496420048	16.76	61.61	10.18	346508	32.70876532	CS

MRUS - Frequently Asked Questions (FAQ)

What is the current Merus NV share price?

The current share price of Merus NV is US$ 40.81

How many Merus NV shares are in issue?

Merus NV has 68,463,681 shares in issue

What is the market cap of Merus NV?

The market capitalisation of Merus NV is USD 2.85B

What is the 1 year trading range for Merus NV share price?

Merus NV has traded in the range of US$ 35.06 to US$ 61.61 during the past year

What is the reporting currency for Merus NV?

Merus NV reports financial results in USD

What is the latest annual turnover for Merus NV?

The latest annual turnover of Merus NV is USD 43.95M

What is the latest annual profit for Merus NV?

The latest annual profit of Merus NV is USD -154.94M

What is the registered address of Merus NV?

The registered address for Merus NV is UPPSALALAAN 17, UTRECHT, UTRECHT, 3584 CT

What is the Merus NV website address?

The website address for Merus NV is www.merus.nl

Which industry sector does Merus NV operate in?

Merus NV operates in the GEN MED & SURGICAL HOSPITALS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
TCTMTCTM Kids IT Education Inc	US$ 0.764 (321.87%)	729.72M
REBNReborn Coffee Inc	US$ 3.31 (63.05%)	55.54M
FCUVFocus Universal Inc	US$ 5.87 (56.62%)	1.73M
SOPASociety Pass Inc	US$ 1.54 (56.50%)	13.82M
CYCNCyclerion Therapeutics Inc	US$ 3.92 (54.33%)	82.39M
ENVBEnveric Biosciences Inc	US$ 2.0899 (-46.41%)	1.57M
NIVFNewGenIvf Group Ltd	US$ 0.1489 (-42.51%)	14.8M
GLSTGlobal Star Acquisition Inc	US$ 8.83 (-39.10%)	23.89k
PRPHProPhase Labs Inc	US$ 0.2633 (-38.02%)	872.46k
SPGCSacks Parente Golf Inc	US$ 0.5601 (-37.86%)	7.27M
TCTMTCTM Kids IT Education Inc	US$ 0.764 (321.87%)	729.72M
NVDANVIDIA Corporation	US$ 120.07 (-3.67%)	388.54M
RIMEAlgorhythm Holdings Inc	US$ 0.02565 (5.12%)	338.75M
BHATBlue Hat Interactive Entertainment Technology	US$ 0.0355 (-11.25%)	236.29M
CLEUChina Liberal Education Holdings Ltd	US$ 0.1938 (30.77%)	234.8M